Cogent Biosciences, Inc. (COGT) stock analysis
In our weekly check, Cogent Biosciences, Inc. is graded D (A to F). Of 19 checks on debt, profit, cash flow and trend: 6 pass, warnings: 4, red flags: 9.
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as COGT.
What our checks show for COGT
Red flags
- The company has net debt but no positive operating earnings (EBITDA) to service it from (debt/equity 0.47).
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- Earnings per share grew only 0.9% a year over the last 3 years.
- The company has no revenue yet.
- Free cash flow is negative and the company has no revenue yet: it lives on its cash and new funding.
- The stock has fallen as much as 98% from a peak. Would you have held through that?
- The share count grew by 102% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- Analysts expect earnings per share to shrink about 40.5% a year.
- The price swings a lot: 45.9% annual volatility. Expect large ups and downs.
- The stock is still below its previous peak.
Strengths
- Analysts expect the net margin to improve by 7.6 points from today's 0%.
- Beta 0.34: the stock usually moves less than the market.
- Actively traded: about 2 million shares a day.
Similar companies
EWTX · TVTX · IONS · DNTH · ADPT · SRRK
Questions
What grade does Cogent Biosciences, Inc. (COGT) have?
In our weekly check, Cogent Biosciences, Inc. is graded D (A to F). Of 19 checks on debt, profit, cash flow and trend: 6 pass, warnings: 4, red flags: 9. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of COGT stock?
This week's biggest flags for Cogent Biosciences, Inc.: High debt, Weak interest cover, Weak EPS growth. In total 13 of 19 checks show a warning or a red flag.
What does Cogent Biosciences, Inc. do?
Cogent Biosciences, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as COGT.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis